公开(公告)号：US20050227978A1

公开(公告)日：2005-10-13

申请号：US10502933

申请日：2003-01-28

申请人： Teruhisa Tokunaga ,  Willian Hume ,  Makoto Kitoh ,  Ryu Nagata ,  Michiko Kishino ,  Tsutomu Nakagawa ,  Jun Nagamine ,  Mutsuo Taiji

发明人： Teruhisa Tokunaga ,  Willian Hume ,  Makoto Kitoh ,  Ryu Nagata ,  Michiko Kishino ,  Tsutomu Nakagawa ,  Jun Nagamine ,  Mutsuo Taiji

IPC分类号： A61K31/381 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4174 ,  A61K31/425 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/5377 ,  A61P11/00 ,  A61P13/12 ,  A61P17/00 ,  A61P43/00 ,  C07D207/32 ,  C07D207/333 ,  C07D233/64 ,  C07D401/06 ,  A61K31/401 ,  A61K31/4164

CPC分类号： C07D207/333 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4174 ,  A61K31/425 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/5377 ,  C07D401/06

摘要： Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is —CO—, —SO2—, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2): (1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

摘要翻译： 药物用作器官或组织的纤维化抑制剂，其包含式（I）的化合物：其中环Z是任选取代的吡咯环等; W 2是-CO - ， - SO 2 - ，任选取代的C 1 -C 4亚烷基等 。 Ar 2是任选取代的芳基等; （1）和（2）：（1）W 1是任选取代的C 1 亚烷基等; 任选取代的具有1至4个氮原子的双环杂芳基作为成环原子：（2）W 1是任选取代的C 2 - -C 5亚烷基，任选取代的C 2 -C 5亚烯基等; 和Ar 1是在相邻或相对于W 1的结合位置的邻位或间位被羧基，烷氧基羰基等取代的芳基或单环杂芳基 >，或其药学上可接受的盐。

公开(公告)号：US06391312B1

公开(公告)日：2002-05-21

申请号：US09355098

申请日：1999-07-23

申请人： Michiko Kishino ,  Chikao Nakayama ,  Mutsuo Taiji ,  Junji Ichihara ,  Hiroshi Noguchi

发明人： Michiko Kishino ,  Chikao Nakayama ,  Mutsuo Taiji ,  Junji Ichihara ,  Hiroshi Noguchi

IPC分类号： A61K3900

CPC分类号： A61K38/185

摘要： The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

摘要翻译： 本发明提供了用于治疗糖尿病和高脂血症的治疗剂，特别是用于治疗II型糖尿病的治疗剂，其包括作为活性成分的神经营养因子如BDNF（脑源性神经营养因子），trkB的配体或 trkC受体，NGF，NT-3，NT-4/5，CNTF，GDNF，HGF等。与常规口服降糖药不同，主要用于治疗II型糖尿病，本发明的药物显示血脂 调节作用和体内脂肪蓄积调节作用，除血糖调节作用外。 因此，本发明的药剂是新颖的，并且可以在不使用任何其它药剂的情况下降低伴有高脂血症或肥胖症的糖尿病的危险因素。

公开(公告)号：US06472366B2

公开(公告)日：2002-10-29

申请号：US10055380

申请日：2002-01-25

申请人： Michiko Kishino ,  Chikao Nakayama ,  Mutsuo Taiji ,  Junji Ichihara ,  Hiroshi Noguchi

发明人： Michiko Kishino ,  Chikao Nakayama ,  Mutsuo Taiji ,  Junji Ichihara ,  Hiroshi Noguchi

IPC分类号： A61K3900

CPC分类号： A61K38/185

摘要： The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

摘要翻译： 本发明提供了用于治疗糖尿病和高脂血症的治疗剂，特别是用于治疗II型糖尿病的治疗剂，其包括作为活性成分的神经营养因子如BDNF（脑源性神经营养因子），trkB的配体或 trkC受体，NGF，NT-3，NT-4/5，CNTF，GDNF，HGF等。与常规口服降糖药不同，主要用于治疗II型糖尿病，本发明的药物显示血脂 调节作用和体内脂肪蓄积调节作用，除血糖调节作用外。 因此，本发明的药剂是新颖的，并且可以在不使用任何其它药剂的情况下降低伴有高脂血症或肥胖症的糖尿病的危险因素。